Bioquell surges on offer from Bill Gates-backed Ecolab
30th Nov 2018 08:49
(Sharecast News) - Bioquell shares surged on Friday as it agreed to be bought by US hygiene company Ecolab for £140.5m.
Read moreBioquell lifts H1 profit, restructures management
24th Aug 2016 15:41
(ShareCast News) - Bioquell has booked a first-half pre-tax profit of £378,000, from a profit of £69,000. Revenue slipped to £12.1m, from £12.5m. It cited cost reduction for the improved profitability as it implemented several management changes. It said, following a strategic review, that sharehold
Read moreTuesday broker round-up
26th Aug 2014 10:16
Bioquell: N+1 Singer upgrades from hold to buy with an unchanged target price of 112p. Investec cuts target price from 133p to 98p, while upgrading from hold to add. Circle Oil: Investec moves target price from 50p to 70p and maintains a buy recommendation. Clinigen Group: N+1 Singer ups target pr
Read moreSector movers: Smith & Nephew lifts defensive healthcare stocks
1st Aug 2014 14:19
The healthcare sector was the only category in positive territory on Friday as investors sought defensive stocks in the face of a wider market sell-off. Meanwhile, results from medical devices maker Smith & Nephew were also encouraging investors in the healthcare space after modestly beating foreca
Read moreFriday broker round-up UPDATE
16th May 2014 08:23
Ashcourt Rowan: N+1 Singer initiates with a target price of 231p and a buy recommendation. Bioquell: N+1 Singer cuts target price from 157p to 112p and downgrades to hold. Boohoo.com: Jefferies initiates with a target price of 68p and a buy recommendation. Capital & Regional: Numis upgrades from
Read moreThursday broker round-up UPDATE
15th May 2014 09:43
Anglo American: Credit Suisse ups target price from 1800p to 1850p downgrading to neutral. ASOS: Berenberg initiates with a target price of 5350p and a buy recommendation. Barclays: Jefferies lowers target price from 345p to 325p, while staying with its buy recommendation. Bioquell: N+1 Singer pl
Read moreTuesday broker round-up UPDATE
18th Mar 2014 08:58
Antofagasta: Investec places its target price (prev.: 753p) under review, while leaving its sell recommendation unchanged. Ashtead Group: Credit Suisse raises target price from 1000p to 1100p and stays with its outperform rating. UBS increases target price from 875p to 1020p retaining its buy recom
Read moreBioquell names Michael Roller as the new Finance Director
21st Jan 2014 15:04
Bio-decontamination equipment products manufacturer Bioquell announced on Tuesday the appointment of Michael Roller as the group's new Finance Director. Roller qualified as an accountant with KPMG and has ample experience in the finance function, including within the life sciences sector. His mo
Read moreSoco International Chairman adds 50,000 shares
13th Dec 2013 15:43
Soco International's Non-Executive Chairman, Rui de Sousa, has acquired 50,000 shares in the international oil and gas exploration and production company. The shares were purchased at 384.97p each for a total spend of £192,485. In its interim management statement last month the group said it was
Read moreFriday broker round-up UPDATE
15th Nov 2013 07:38
Amlin: Berenberg raises target price from 398p to 434p, but still recommends selling. Barclays cuts target price from 481p to 453p and retains an overweight rating. Antofagasta: Numis raises target price from 750p to 850p and reiterates a hold recommendation. AstraZeneca: Liberum Capital upgrades
Read moreThursday broker round-up UPDATE
5th Sep 2013 08:03
AMEC: Nomura reduces target price from 1300p to 1230p, while reiterating its buy recommendation. Antofagasta: Exane cuts target price from 1200p to 1100p maintaining an outperform rating. Ashtead Group: JP Morgan shifts target price from 729p to 734p and keeps a neutral rating. Associated British
Read moreTuesday broker round-up UPDATE
19th Mar 2013 07:21
Admiral Group: Canaccord Genuity raises target price from 1050p to 1215p, but reiterates its sell recommendation. BAE Systems: Investec moves target price from 325p to 375p retaining a hold recommendation. Balfour Beatty: Numis lowers target price from 330p to 300p and downgrades to add. BHP Bill
Read moreBioquell profits hit by problematic December
14th Jan 2013 12:11
Bioquell, a company which provides specialist bio-decontamination technologies to a range of markets, has admitted it suffered a 'slight shortfall' at the end of the year in orders expected for immediate shipment to Life Sciences customers based in continental Europe. As a result, full year revenue
Read moreMonday broker round-up UPDATE
14th Jan 2013 06:57
Aberdeen Asset Management: JP Morgan ups target price from 414p to 479p and retains an overweight rating. HSBC downgrades to neutral. Aggreko: UBS cuts target price from 2350p to 2250p maintaining a buy rating. ARM Holdings: Piper Jaffray downgrade to neutral. Ashmore Group: JP Morgan shifts ta
Read moreOverheads hurt profits at Bioquell
15th Mar 2011 15:41
Despite a slow start in 2010 for bio-decontamination technology group Bioquell, revenues grew 1%, but higher overheads resulted in a 44% fall in profits. Revenue for the year ended 31 December grew to £39.4m, from £39.2m, while total orders increased 24% from £36.2m to £44.8m. The first half saw a
Read more